NEW YORK, Oct. 9, 2012 /PRNewswire/ -- IntelliCell BioSciences, Inc. (“Company”) (SVFC) announced today that it has been successful in manufacturing stromal vascular cells from Non-Living adipose tissue from a deceased tissue donor. These cells have been grown in culture and demonstrated to have the correct CD antibody markers for mesenchymal stem cells and other cells that are consistent with stromal vascular fraction cells.
The provisional patent, titled “ISOLATION OF STROMAL VASCULAR FRACTION FROM NON-LIVING ADIPOSE TISSUE USING ULTRASONIC CAVITATION” expands the field of cellular therapy, and specifically, research in adipose stromal vascular fraction (SVF).
For the first time, SVF will be harvested from non-living adipose tissue, cultured to identify the cellular characteristics, and will be provided for clinical research purposes. Previously, only physicians performing liposuction could supply samples of lipoaspirate cells that are then processed to yield stromal vascular fraction (SVF) cells.
According to IntelliCell’s Chairman and CEO, Dr. Steven Victor, “This could be transformational for the research field of stromal vascular fraction cells. SVF cells from adipose tissue may soon be readily available for researchers and institutions around the world to study and advance the field of cellular therapy with SVF’s. This is an exciting discovery, yet there is significant work yet to be done before commercialization.”
Robert J. Sexauer, EVP of Clinical Development, stated, “Much as organ donation has saved many, many lives, this process can lead to the development of new lifesaving treatments.”
IntelliCell recognizes that SVF therapies are an important part in the future of Regeneration Medicine.
According to BioInformant Worldwide LLC, “There is conclusive evidence that entering the stem cell research products market is fiscally worthwhile. Full-year 2011 analysis determines the size the stem cell research products market to be $2.59 billion, and the stem cell therapies market to be $3.13 billion, for a total of $5.72 billion. In addition, both markets are growing with double-digit growth. Producing stem cell research products thus represents a massive profit opportunity for research supply companies.”
About IntelliCell BioSciences
IntelliCell is a pioneering regenerative medicine company focused on the expanding regenerative medical markets using adult autologous vascular cells (SVC’s) derived from the blood vessels in the adult adipose tissue. IntelliCell Biosciences has developed its own patent pending protocol to separate adult autologous vascular cells from adipose tissue without the use of enzymes. IntelliCell will also be seeking to develop technology-licensing agreements with technology developers, universities, and international business entities.
Forward-Looking Statements
Certain statements set forth in this press release constitute “forward-looking statements.” Forward-looking statements include, without limitation, any statement that may predict, forecast, indicate, or imply future results, performance or achievements, and may contain the words “estimate,” “project,” “intend,” “forecast,” “anticipate,” “plan,” “planning,” “expect,” “believe,” “will likely,” “will reach,” “will change,” “will soon,” “should,” “could,” “would,” “may,” “can” or words or expressions of similar meaning. Such statements are not guarantees of future performance and are subject to risks and uncertainties that could cause the company’s actual results and financial position to differ materially from those included within the forward-looking statements. Forward-looking statements involve risks and uncertainties, including those relating to the Company’s ability to grow its business. Actual results may differ materially from the results predicted and reported results should not be considered as an indication of future performance. The potential risks and uncertainties include, among others, the Company’s limited operating history, the limited financial resources, domestic or global economic conditions, activities of competitors and the presence of new or additional competition, and changes in Federal or State laws. More information about the potential factors that could affect the Company’s business and financial results is included in the Company’s filings, available via the United States Securities and Exchange Commission.
Contacts:
IntelliCell BioSciences, Inc.
Robert J. Sexauer
Email Contact: rsexauer@intellicellbiosciences.com
(646) 576-8706
SOURCE IntelliCell BioSciences, Inc.
